Literature DB >> 6253567

Circulating immune complexes associated with naturally occurring lymphosarcoma in pet cats.

N K Day, C O'Reilly-Felice, W D Hardy, R A Good, S S Witkin.   

Abstract

Cats were classified into 4 categories by immunofluorescence antibody assay for the presence of feline leukemia virus (FeLV) and histologically as a) normal, FeLV-, b) normal, FeLV+, c) lymphosarcoma (LSA), FeLV+, and d) LSA, FeLV-. Determinations by Raji cell radioimmunoassay modified for cat serum revealed circulating immune complex (CIC) levels of healthy cats to be less than or equal to 50 micrograms equivalent aggregated cat immunoglobulin/ml (microgram/ml). In contrast, sera of cats in groups b, c, and d all contained significantly higher CIC levels (up to 12,000 micrograms/ml) associated with marked hypocomplementemia and C activation occurring via the classical pathway. Sera from FeLV+, LSA+ cats with high levels of CIC and sera of healthy cats were fractionated according to size and bouyant density by centrifugation through 10 to 40% sucrose gradients. Analysis of fractions from LSA+, FeLV+ sera revealed that both immune complexes (ICs), FeLV reverse transcriptase (RT), and IgG were present in fractions corresponding to a bouyant density of 1.15 to 1.18 g/ml. The CIC containing fractions activated C by the classical pathway. Sera from normal cats did not have CIC or RT and none of the fractions activated the classical pathway. These data suggest that vital antigen-antibody complexes are present in sera of viremic cats with LSA and these complexes activate the C system.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253567

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Effects of cobra venom factor treatment on latent feline leukemia virus infection.

Authors:  E H Kraut; J L Rojko; R G Olsen; D L Tuomari
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

Review 2.  Immunopathology induced by the feline leukemia virus.

Authors:  W D Hardy
Journal:  Springer Semin Immunopathol       Date:  1982

3.  Immunoselection of tumor variants resistant to antibody-mediated cytotoxicity. Their immunologic and metastatic characterization.

Authors:  J R Starkey; W C Davis; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Immunologic enhancement of experimental metastasis in the rat.

Authors:  J R Starkey; S S Ristow; T L McDonald; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets.

Authors:  R Hofmann-Lehmann; E Holznagel; P Ossent; H Lutz
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

Review 6.  Feline leukemia/sarcoma viruses and immunodeficiency.

Authors:  J Rojko; M Essex; Z Trainin
Journal:  Adv Vet Sci Comp Med       Date:  1988

Review 7.  Clinical aspects of feline immunodeficiency and feline leukemia virus infection.

Authors:  Katrin Hartmann
Journal:  Vet Immunol Immunopathol       Date:  2011-07-21       Impact factor: 2.046

Review 8.  Clinical aspects of feline retroviruses: a review.

Authors:  Katrin Hartmann
Journal:  Viruses       Date:  2012-10-31       Impact factor: 5.048

Review 9.  The immunobiology of the feline leukemia virus.

Authors:  J L Rojko; R G Olsen
Journal:  Vet Immunol Immunopathol       Date:  1984-05       Impact factor: 2.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.